Significance of serum glucagon-like peptide-1 and matrix Gla protein levels in patients with diabetes and osteoporosis

doi:10.12998/wjcc.v10.i5.1527

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 5

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3725)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

215

WORD

HTML

1895

Figures (1-1)

247

Tables (1-6)

251

Sum=2701

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

335

Download

689

Sum=1024

Feb 16, 2022 (publication date) through Jul 28, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Feb 16, 2022; 10(5): 1527-1535
Published online Feb 16, 2022. doi: 10.12998/wjcc.v10.i5.1527

Table 1 Single factor analysis of general data of the three groups of study participants, n (%)

Factors	Case group (n = 60)	Control group (n = 60)	Healthy group (n = 60)	F/χ²/t	P value
Age (yr)	66.78 ± 5.85	61.83 ± 5.36	61.92 ± 5.48	15.563	0.000
Course of disease (yr)	12.99 ± 4.01	8.98 ± 3.83	-	5.601	0.000
BMI (kg/m²)	24.52 ± 2.32	24.73 ± 2.49	23.68 ± 2.05	3.510	0.032
FPG (mmol/L)	8.50 ± 1.50	8.27 ± 1.24	5.77 ± 0.61	99.314	0.000
HbA1c (%)	9.18 ± 1.12	8.76 ± 1.26	5.89 ± 0.70	184.683	0.000
Sex				5.896	0.052
Male	15 (25.00)	25 (41.67)	27 (45.00)
Female	45 (75.00)	35 (58.33)	33 (55.00)
Smoking				2.553	0.279
Yes	9 (15.00)	16 (26.67)	14 (23.33)
No	51 (85.00)	44 (73.33)	46 (76.67)
Drinking				2.182	0.336
Yes	7 (11.67)	11 (18.33)	13 (21.67)
No	53 (88.33)	49 (81.67)	47 (78.33)
Hypertension				23.054	0.000
Yes	15 (25.00)	20 (33.33)	0 (0.00)
No	45 (75.00)	40 (66.67)	60 (100.00)
Coronary heart disease				9.449	0.009
Yes	5 (8.33)	9 (15.00)	0 (0.00)
No	55 (91.67)	51 (85.00)	60 (100.00)

BMI: body mass index; FPG: Fasting plasma glucose.

Table 2 Comparison of serum glucagon-like peptide-1 and matrix Gla protein levels in the three groups of study participants (mean ± SD)

Group	n	GLP-1 (pmol/L)	MGP (nmol/L)
Case group	60	9.19 ± 1.10	7.88 ± 0.92
Control group	60	13.88 ± 1.65	9.77 ± 1.52
Healthy group	60	17.07 ± 2.48	10.79 ± 1.63
F		280.527	67.487
P value		0.000	0.000

GLP-1: Glucagon-like peptide-1; MGP: Matrix Gla protein.

Table 3 Comparison of bone density and bone metabolic marker levels of the three groups of study participants (mean ± SD)

Group	n	Lumbar spine (g/m²)	Hip joint (g/m²)	BALP (μg/mL)	P1NP (ng/mL)	BGP (μgmL)	β-CTX (ng/mL)
Case group	60	0.69 ± 0.08	0.66 ± 0.09	4.08 ± 1.20	49.16 ± 4.08	15.92 ± 4.08	0.49 ± 0.08
Control group	60	0.95 ± 0.14	0.83 ± 0.10	4.03 ± 0.84	44.41 ± 2.75	14.40 ± 2.75	0.44 ± 0.08
Healthy group	60	1.08 ± 0.16	0.99 ± 0.14	4.07 ± 0.82	31.59 ± 2.38	12.14 ± 2.38	0.41 ± 0.10
F		142.637	130.422	0.036	122.211	21.822	14.496
P value		0.000	0.000	0.965	0.000	0.000	0.000

BALP: Bone alkaline phosphatase; P1NP: Type 1 procollagen amino-terminal propeptide; BGP: Osteocalcin; β-CTX: Special sequence of carboxy-terminal peptide β of type 1 collagen.

Table 4 Correlation analysis results

Index	Relativity	Lumbar spine (g/m²)	Hip joint (g/m²)
GLP-1 (pmol/L)	r	0.707	0.691
GLP-1 (pmol/L)	P value	0.000	0.000
MGP (nmol/L)	r	0.571	0.546
MGP (nmol/L)	P value	0.000	0.000

GLP-1: Glucagon-like peptide-1; MGP: Matrix Gla protein.

Table 5 Correlation between serum glucagon-like peptide-1, matrix Gla protein levels, and bone metabolism marker levels

Index	Relativity	BALP (μg/mL)	P1NP (ng/mL)	BGP (μgmL)	β-CTX (ng/mL)
GLP-1 (pmol/L)	r	0.192	-0.401	-0.386	-0.377
GLP-1 (pmol/L)	P value	0.163	0.000	0.003	0.005
MGP (nmol/L)	r	0.155	-0.421	-0.419	-0.351
MGP (nmol/L)	P value	0.227	0.000	0.000	0.010

GLP-1: Glucagon-like peptide-1; MGP: Matrix Gla protein; BALP: Bone alkaline phosphatase; P1NP: Type 1 procollagen amino-terminal propeptide; BGP: Osteocalcin; β-CTX: Special sequence of carboxy-terminal peptide β of type 1 collagen.

Table 6 Factor analysis of the logistic regression model

Index		SE	Walds	P value	OR	95%CI
Age	0.551	0.225	5.997	0.007	1.735	1.116	2.697
Course of disease	0.494	0.240	4.237	0.048	1.639	1.024	2.623
BMI	0.381	0.211	3.261	0.094	1.464	0.968	2.213
FPG	0.307	0.184	2.784	0.116	1.359	0.948	1.950
HbA1c	0.502	0.316	2.524	0.131	1.652	0.889	3.069
Hypertension	0.484	0.408	1.407	0.248	1.623	0.729	3.610
Coronary heart disease	0.490	0.411	1.421	0.241	1.632	0.729	3.653
GLP-1	-0.616	0.277	4.945	0.039	0.540	0.314	0.930
MGP	-0.573	0.254	5.089	0.037	0.564	0.343	0.928
β-CTX	0.184	0.152	1.465	0.237	1.202	0.892	1.619
BALP	0.207	0.182	1.294	0.301	1.230	0.861	1.757
BGP	0.118	0.104	1.287	0.316	1.125	0.918	1.380

BMI: body mass index; FPG: Fasting plasma glucose; GLP-1: Glucagon-like peptide-1; MGP: Matrix Gla protein; BALP: Bone alkaline phosphatase; P1NP: Type 1 procollagen amino-terminal propeptide; BGP: Osteocalcin; β-CTX: Special sequence of carboxy-terminal peptide β of type 1 collagen.

Citation: Xie FF, Zhang YF, Hu YF, Xie YY, Wang XY, Wang SZ, Xie BQ. Significance of serum glucagon-like peptide-1 and matrix Gla protein levels in patients with diabetes and osteoporosis. World J Clin Cases 2022; 10(5): 1527-1535
URL: https://www.wjgnet.com/2307-8960/full/v10/i5/1527.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i5.1527